Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

β-defensin genomic copy number is associated with HIV load and immune reconstitution in sub-saharan Africans.

Hardwick RJ, Amogne W, Mugusi S, Yimer G, Ngaimisi E, Habtewold A, Minzi O, Makonnen E, Janabi M, Machado LR, Viskaduraki M, Mugusi F, Aderaye G, Lindquist L, Hollox EJ, Aklillu E.

J Infect Dis. 2012 Oct 1;206(7):1012-9. doi: 10.1093/infdis/jis448. Epub 2012 Jul 26.

2.

CCL3L1 copy number, HIV load, and immune reconstitution in sub-Saharan Africans.

Aklillu E, Odenthal-Hesse L, Bowdrey J, Habtewold A, Ngaimisi E, Yimer G, Amogne W, Mugusi S, Minzi O, Makonnen E, Janabi M, Mugusi F, Aderaye G, Hardwick R, Fu B, Viskaduraki M, Yang F, Hollox EJ.

BMC Infect Dis. 2013 Nov 12;13:536. doi: 10.1186/1471-2334-13-536.

3.

Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD; HepaI.Co.N.A. Study Group; Italian Cohort Naive for Antiretrovirals Study Group.

Clin Infect Dis. 2005 Jun 15;40(12):e101-9. Epub 2005 May 5.

4.

Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.

Laurichesse JJ, Persoz A, Theodorou I, Rouzioux C, Delfraissy JF, Meyer L.

HIV Med. 2007 May;8(4):213-9.

5.

Copy number variation of Fc gamma receptor genes in HIV-infected and HIV-tuberculosis co-infected individuals in sub-Saharan Africa.

Machado LR, Bowdrey J, Ngaimisi E, Habtewold A, Minzi O, Makonnen E, Yimer G, Amogne W, Mugusi S, Janabi M, Aderaye G, Mugusi F, Viskaduraki M, Aklillu E, Hollox EJ.

PLoS One. 2013 Nov 8;8(11):e78165. doi: 10.1371/journal.pone.0078165. eCollection 2013.

6.

Effect of influenza virus vaccine on the expression of human immunodeficiency virus co-receptor CCR5.

Rucker RP, Day NK, Good RA, Kamchaisatian W, Emmanuel P, Sleasman JW, Mayeski C, Dinglasan E, Haraguchi S, Tangsinmankong N.

Ann Allergy Asthma Immunol. 2004 Sep;93(3):272-6.

PMID:
15478388
7.

Poor immune reconstitution in HIV-infected patients associates with high percentage of regulatory CD4+ T cells.

Horta A, Nobrega C, Amorim-Machado P, Coutinho-Teixeira V, Barreira-Silva P, Boavida S, Costa P, Sarmento-Castro R, Castro AG, Correia-Neves M.

PLoS One. 2013;8(2):e57336. doi: 10.1371/journal.pone.0057336. Epub 2013 Feb 20.

9.

Residual viraemia in HIV-1-infected patients with plasma viral load <or=20 copies/ml is associated with increased blood levels of soluble immune activation markers.

Ostrowski SR, Katzenstein TL, Pedersen BK, Gerstoft J, Ullum H.

Scand J Immunol. 2008 Dec;68(6):652-60. doi: 10.1111/j.1365-3083.2008.02184.x.

10.

Responsiveness of T cells to interleukin-7 is associated with higher CD4+ T cell counts in HIV-1-positive individuals with highly active antiretroviral therapy-induced viral load suppression.

Camargo JF, Kulkarni H, Agan BK, Gaitan AA, Beachy LA, Srinivas S, He W, Anderson S, Marconi VC, Dolan MJ, Ahuja SK.

J Infect Dis. 2009 Jun 15;199(12):1872-82. doi: 10.1086/598858.

11.

Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy.

Price P, Mathiot N, Krueger R, Stone S, Keane NM, French MA.

J Clin Virol. 2001 Oct;22(3):279-87.

PMID:
11564593
12.

CD4 T cell count reconstitution in HIV controllers after highly active antiretroviral therapy.

Okulicz JF, Grandits GA, Weintrob AC, Landrum ML, Ganesan A, Crum-Cianflone NF, Agan BK, Marconi VC.

Clin Infect Dis. 2010 Apr 15;50(8):1187-91. doi: 10.1086/651421.

13.

HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy.

Lincoln D, Petoumenos K, Dore GJ; Australian HIV Observational Database.

HIV Med. 2003 Jul;4(3):241-9.

14.

Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study.

Yamashita TE, Phair JP, Muñoz A, Margolick JB, Detels R, O'Brien SJ, Mellors JW, Wolinsky SM, Jacobson LP.

AIDS. 2001 Apr 13;15(6):735-46.

PMID:
11371688
15.

HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART.

Soulié C, Marcelin AG, Ghosn J, Amellal B, Assoumou L, Lambert S, Duvivier C, Costagliola D, Katlama C, Calvez V.

AIDS. 2007 Oct 18;21(16):2243-5.

PMID:
18090053
16.

Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.

Smith CJ, Sabin CA, Youle MS, Kinloch-de Loes S, Lampe FC, Madge S, Cropley I, Johnson MA, Phillips AN.

J Infect Dis. 2004 Nov 15;190(10):1860-8. Epub 2004 Oct 8.

17.

Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy.

Kroon FP, Rimmelzwaan GF, Roos MT, Osterhaus AD, Hamann D, Miedema F, van Dissel JT.

AIDS. 1998 Dec 3;12(17):F217-23.

PMID:
9863863
18.

CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals.

Ahuja SK, Kulkarni H, Catano G, Agan BK, Camargo JF, He W, O'Connell RJ, Marconi VC, Delmar J, Eron J, Clark RA, Frost S, Martin J, Ahuja SS, Deeks SG, Little S, Richman D, Hecht FM, Dolan MJ.

Nat Med. 2008 Apr;14(4):413-20. doi: 10.1038/nm1741. Epub 2008 Mar 30.

19.

Criteria for initiating highly active antiretroviral therapy and short-term immune response among HIV-1-infected patients in Côte d'Ivoire.

Diabaté S, Alary M.

HIV Med. 2009 Nov;10(10):640-6. doi: 10.1111/j.1468-1293.2009.00736.x. Epub 2009 Jul 29.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk